Anaphylaxis secondary to chymopapain.

Area of Science:

• Anesthesiology
• Pharmacology

Background:

• Chymopapain is an enzyme used in medical treatments.
• Anaphylaxis is a severe allergic reaction.
• The study investigates anaphylaxis incidence and management related to chymopapain.

Discussion:

• Anaphylaxis affects approximately 1% of patients receiving chymopapain.
• Women exhibit a significantly higher incidence of chymopapain-induced anaphylaxis compared to men.
• Pretreatment with H1- and H2-histamine receptor antagonists can potentially mitigate the severity of anaphylactic reactions.
• Immediate and appropriate medical intervention is essential for managing anaphylaxis once it develops.

Key Insights:

• Chymopapain-associated anaphylaxis risk is around 1%.
• Female patients have a tenfold higher risk of anaphylaxis.
• Histamine receptor antagonists may attenuate anaphylaxis severity.
• Timely treatment is critical for anaphylaxis management.

Outlook:

• Further research into prophylactic strategies for chymopapain-induced anaphylaxis.
• Investigating the specific mechanisms behind the higher incidence in women.
• Optimizing treatment protocols for anaphylaxis following chymopapain administration.